Why Genome Computer is operated by a Public Benefit Corporation

Genome Computer asks you to do something unusually intimate: turn your genome into a file that software can actually work with.

That file can be powerful. A .genome bundle can help Codex or Claude Code search your variants, check the latest literature, build personal tools, and explain what a new discovery might mean in the context of your biology.

But the same thing that makes genomic data useful makes it different from ordinary user data. It is persistent. It is identifying. It says something about you, and often something about people related to you. If a company treats it like another growth asset, the whole project is already pointed in the wrong direction.

That is why The Genome Computer Company is operated by Genetic Superintelligence Company, a Delaware Public Benefit Corporation.

Privacy should not depend on good intentions

Most privacy promises are written for the present tense. We will not do this. We do not do that. Those promises matter, but they are weak on their own because companies change.

Leadership changes. Markets change. Investors change. Acquirers arrive with new plans. A privacy policy can be rewritten. A product strategy can be reframed. A database that was collected for one purpose can slowly become the most tempting asset on the balance sheet.

Genomic data cannot be protected by good intentions alone. It needs structures that still mean something when there is pressure to do the easier, more profitable, more extractive thing.

What a Public Benefit Corporation changes

A Public Benefit Corporation is still a company. It has to operate sustainably. It has customers, costs, and shareholders.

The difference is that a PBC is not governed only around shareholder return. Its directors must also consider the company’s stated public benefit and the people affected by the company’s actions. That purpose is part of the legal structure of the entity, not a campaign line on a homepage.

For Genome Computer, the public benefit commitment is about advancing human understanding while keeping identifiable individual genomic data under individual control and off the market. In plain terms: we do not sell or license your individual genetic data.

That matters most when the incentive is strongest. If a board were asked to sell identifiable genomic data because it would make the company more valuable, the PBC structure changes the question. The board has to consider whether doing so violates the company’s public benefit and the people whose data made the company possible.

The prohibition is the product

We are not building a research-consent funnel. We are not collecting a database to resell later. We are not asking you to donate your DNA so that someone else can monetize it.

The service is deliberately narrower: sequence your sample or convert your existing file, annotate it, deliver it as an AI-readable .genome bundle, and let you decide what to do with it.

Our privacy policy states the constraint explicitly. We do not sell your data. We do not share it with researchers, pharmaceutical companies, insurers, or law enforcement except where compelled by valid legal process. We do not use identifiable genomic data to train AI models. We do not sell, license, or commercially distribute aggregated or de-identified genomic datasets.

There is no optional research program hidden behind the purchase. The thing you are buying is your genome, in a format that is useful to you.

Why this matters more with AI

AI changes the surface area of genomics. A PDF report is static. A portal is bounded by whatever screens the company built. A .genome bundle connected to an agent is open-ended: it can be queried, joined against new papers, reinterpreted against new references, and used as context for personal software.

That is the point of Genome Computer. Your genome should be something your tools can reason over, not something locked inside a dashboard.

Open-ended usefulness requires open-ended trust. If an agent can help you understand your genome, you need confidence that the company supplying the file is not quietly building a second business around the same data. You should not need to wonder whether every new capability is also a new extraction surface.

The PBC structure is one part of that answer. It does not replace encryption, scoped access, deletion rights, careful subprocessors, or boring operational security. It sits underneath them. It says the company itself is built around the constraint that your identifiable genomic data remains yours.

Control has to survive the lifecycle

A genome is not a one-time upload. It is a lifelong data asset. The science will change. The tools will change. The companies around the tools will change too.

So our commitment has to be durable across the lifecycle of the data: collection, sequencing, annotation, delivery, redelivery, deletion, agent access, and whatever interfaces come next.

That is why the service is built around user-controlled files, not an advertising model or a research marketplace. Your .genome bundle is delivered to you. Access through Genome Computer is account-authorized and revocable. If you request deletion, our systems are designed around deleting genomic content rather than preserving it indefinitely for future monetization.

The company has to match the material

Some products can be built by ordinary companies with ordinary privacy policies. We do not think consumer genomics is one of them.

If we are going to help people bring their genomes into Codex, Claude Code, and whatever personal AI systems come next, the corporate structure has to match the sensitivity of the material. The file format has to make the data legible. The product has to make the data useful. The company has to make the promise credible.

That is why Genome Computer is operated by a Public Benefit Corporation.

Your genome should be useful. It should also remain yours.

Read the Genome Computer Privacy Policy and Terms of Service.